RXRX · Recursion Pharmaceuticals, Inc.
AI read · Neutral
The AI's read
The deals give Recursion $12,000,000 upfront and cut future scheduled fees. They also remove Recursion's right to exit, shrink its data access, and grant Tempus a two-year oncology license. Those positives and negatives largely cancel each other, so the filing does not change how I read Recursion today.